Learn more

Bayer Pharma AG

Overview
  • Total Patents
    4,993
  • GoodIP Patent Rank
    395
  • Filing trend
    ⇩ 51.0%
About

Bayer Pharma AG has a total of 4,993 patent applications. It decreased the IP activity by 51.0%. Its first patent ever was published in 1994. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are GLAXOSMITHKLINE IP NO 2 LTD, TREVENA INC and KISSEI PHARMACEUTICAL CO LTD.

Patent filings per year

Chart showing Bayer Pharma AGs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Lienau Philip 580
#2 Siemeister Gerhard 492
#3 Wunder Frank 347
#4 Vakalopoulos Alexandros 286
#5 Stasch Johannes-Peter 283
#6 Tersteegen Adrian 274
#7 Follmann Markus 258
#8 Lang Dieter 252
#9 Briem Hans 249
#10 Redlich Gorden 231

Latest patents

Publication Filing date Title
WO2021013693A1 Antibody drug conjugates (adcs) with nampt inhibitors
WO2020094471A1 Cytostatic conjugates with integrin ligands
WO2020048828A1 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
EP3781565A1 2-methyl-aza-quinazolines
PE20210165A1 A SUBSTITUTED OXOPYRIDINE DERIVATIVE
US2019307728A1 Methods of treatment with a 2,4,5-trisubstituted 1,2,4-triazolone
EP3774769A1 4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders
WO2019180072A1 Parenteral pharmaceutical composition comprising neladenoson bialanate
US2019240231A1 Reducing the risk of cardiovascular events
US2019177279A1 Carboxylic acid aromatic 1,2-cyclopropylamides
US2019177284A1 Tetrazolyl-containing cyclopropanecarboxamides
US2019194148A1 Tetrazole-containing 1,2-cyclopropane-carboxamides
CN111433204A Process for the preparation of (3S) -3- (4-chloro-3- { [ (2S,3R) -2- (4-chlorophenyl) -4,4, 4-trifluoro-3-methylbutyryl ] amino } phenyl) -3-cyclopropylpropionic acid and crystalline forms thereof for use as a pharmaceutically active substance
CA3084755A1 Process for preparing benzothiophen-2yl boronate
US2020253961A1 Amine substituted triazole derivatives and uses thereof
EP3700898A1 Substituted triazole derivatives and uses thereof
EP3700897A1 Substituted triazole derivatives and uses thereof
EP3700899A1 Substituted triazole derivatives and uses thereof
TW201919636A Formulations of COPANLISIB
WO2019038156A1 Use of an ep4 antagonist for the treatment of arthritis